Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin prophylaxis for TIVAD in solid tumor patients
NCT00867295Phase 3Completed
- Sponsor
- Istanbul University
- Start
- Sep 2008
- Primary completion
- Dec 2009
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefazolin in Infection, sponsored by Istanbul University. Primary endpoint: Infectious complication at 30 days. Started Sep 2008; status: completed.
02
Drugs
cefazolin
03
Conditions
Infection
Beyond the preview
Go deeper on NCT00867295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00867295.